Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

Share Price is delayed by 15 minutes
Get Live Data
25.75    0.00 (0.00%)
Bid:
25.50
Ask:
26.00
Spread: 0.50 (1.961%)
Market Cap: £129.66m
DUKE Live PriceLast checked at - London Stock Exchange

Intraday Duke Capital Share Chart

Trading Update

4 Feb 2021 07:00

RNS Number : 9284N
Duke Royalty Limited
04 February 2021
 

4 February 2021

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Trading Update

Duke Royalty, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, is pleased to provide the following trading and operational update for its third financial quarter ended 31 December 2020 ("Q3 FY21") and to provide guidance on trading for its fourth financial quarter ending 31 March 2021 ("Q4 FY21").

Highlights:

· Cash revenue for Q3 FY21, being cash distributions from Duke's Royalty Partners and cash gains from sales of equity assets, totalled £4.2m which represents a record quarter of cash revenue generation for Duke.

· Within the £4.2m of quarterly cash revenue, £1.7m related to the receipt of the redemption premium generated from the exit of Welltel, which occurred in December 2020. Once this positive effect is stripped out, like for like cash revenue for Q3 FY21 stood at £2.5m. This is in line with management's expectations and represents an increase from the £2.4m reported in Q2 FY21 and £2.0m in Q1 FY21.

· An IRR of 27% was generated from Duke's investment in Welltel. This was the Company's largest investment and represented the second exit of a royalty partner, further validating the Duke investment model.

· Based on current trading, Duke expects cash revenue for Q4 FY21 to be £2.5m, despite Welltel contributing no cash revenue in the quarter. Prior to exit, Welltel was delivering quarterly cash revenue of £450,000, highlighting the ongoing improvement in the cash generation of the existing portfolio.

 

· Duke also announced two separate follow-on transactions in December which included investments into MRDB Holdings Limited and BHPC Limited.

· As a result of the Welltel exit, the two new deployments in Q3 FY21 and the Step Investments deployment that closed in early January 2021, net debt currently stands at £5.6m, significantly below the £14.0m announced on 12 November 2020. This provides Duke with considerable liquidity for new investments.

· On 12 January 2021 Duke announced the appointment of Peter Madouros as Group Chief Investment Officer ("CIO"), in line with its planned succession strategy whereby Jim Webster, Duke's current CIO, will take up the role of Chairman of the Investment Committee. Duke is delighted to have Peter join the investment team while also retaining Jim's experience during both the due-diligence and deal execution process.

· Duke's pipeline remains strong and management is confident of being able to announce additional follow-on as well as new deployments in the near future, in line with market expectations.

Neil Johnson, CEO of Duke Royalty, said:

"I am pleased to report that cash revenue has continued to increase in Q3 FY21 in comparison to Q2 FY21, testament to the resiliency of our portfolio. In the quarter, Duke achieved one major exit and made two follow-on investments, while also expanding the investment team through the appointment of Peter Madouros as CIO.

"While the macro environment remains highly volatile, the pandemic has also presented Duke with a significant growth opportunity. Banks have been tightening SME lending criteria ever since the global financial crisis and demand for more flexible, alternative sources of capital remains very strong. As a first mover and leader in the UK and European corporate royalty space, Duke has a significant opportunity to build and further diversify its portfolio. Importantly, we have significant liquidity available for new deployments, which adds to our high level of confidence as we enter 2021."

 

***ENDS***

 

For further information, please visit www.dukeroyalty.com or contact:

 

Duke Royalty Limited

Neil Johnson / Charlie Cannon Brookes / Hugo Evans

 

 

+44 (0) 1481 741 240

Cenkos Securities plc 

(Nominated Adviser

and Joint Broker)

 

Stephen Keys / Callum Davidson / Julian Morse / Michael Johnson

 

+44 (0) 207 397 8900

 

Canaccord Genuity

(Joint Broker)

 

Adam James / Georgina McCooke

+44 (0) 207 523 8000

SEC Newgate (PR)

Elisabeth Cowell/ Tom Carnegie/ Megan Kovach

+ +44 (0) 20 3757 6880 dukeroyalty@secnewgate.co.uk

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFVDFAIVIIL
Date   Source Headline
20th Mar 20179:35 amRNSSch 1 Update - Duke Royalty Limited
17th Mar 20176:17 pmRNSResult of Fundraising
16th Mar 20175:03 pmRNSProposed Placing and Subscription
21st Feb 201711:25 amRNSSch 1 Update - Duke Royalty Limited
1st Feb 201711:00 amRNSSchedule 1 - Duke Royalty Limited
11th Jan 20177:01 amRNSAppointment of Chief Investment Officer
11th Jan 20177:00 amRNSChange of Advisors and Operational Update
17th Nov 20169:00 amRNSUnaudited interim results
1st Sep 201612:02 pmRNSResult of AGM
25th Jul 20167:00 amRNSFinal Results
29th Mar 20161:32 pmRNSSale of investments
7th Mar 20167:00 amRNSBoard Changes and Corporate Update
3rd Feb 20167:00 amRNSDirector/PDMR Shareholding
19th Jan 20169:55 amRNSChange of Adviser
14th Dec 201511:40 amRNSDirector/PDMR Shareholding
23rd Nov 20157:00 amRNSInterim results
29th Oct 20157:00 amRNSHolding(s) in Company
29th Oct 20157:00 amRNSCorrection: Appointment and Issue of Shares
28th Oct 20157:00 amRNSMr Justin Cochrane Appointment and Issue of Shares
12th Oct 20155:16 pmRNSHolding(s) in Company
17th Sep 20153:40 pmRNSFormation of Healthcare Investment Committee
14th Sep 201512:41 pmRNSHolding(s) in Company
11th Sep 20157:00 amRNSDirector share purchase
10th Sep 201512:00 pmRNSResult of AGM
7th Sep 20159:15 amRNSGrant of options
7th Sep 20157:00 amRNSPlacing
7th Sep 20157:00 amRNSCollaboration with Oliver Wyman
4th Aug 201512:21 pmRNSChanges to NAV Reporting
27th Jul 20154:12 pmRNSResults for the year ended 31 March 2015
16th Jun 201511:36 amRNSResult of EGM
10th Jun 201511:21 amRNSHolding(s) in Company
2nd Jun 20151:57 pmRNSHolding(s) in Company
28th May 201511:00 amRNSEGM, proposed changes to board & investing policy
26th May 20159:58 amRNSHolding(s) in Company
26th May 20159:57 amRNSHolding(s) in Company
26th May 20159:56 amRNSHolding(s) in Company
26th May 20159:56 amRNSHolding(s) in Company
22nd May 20155:15 pmRNSRepayment of zero dividend preference shares
20th May 20157:00 amRNSPlacing
15th May 201511:08 amRNSSale of investment
20th Apr 20155:36 pmRNSNet Asset Value(s)
19th Jan 20154:27 pmRNSNet Asset Value(s)
30th Dec 20143:07 pmRNSInterim Results
9th Dec 20145:23 pmRNSNet Asset Value
3rd Nov 20147:00 amRNSChange of administrator and registered address
22nd Oct 20147:00 amRNSNet Asset Value(s)
20th Aug 20141:54 pmRNSResult of AGM
24th Jul 20147:00 amRNSNet Asset Value(s)
16th Jul 201410:11 amRNSHolding(s) in Company
15th Jul 20147:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.